Clinical Investigation of Sorbact® Dressings
ID: NCT05089890
Our intelligence engine has synthesized this trial record to answer your most important questions in clear, simple terms:
The main purpose of this exploratory clinical investigation is to study the binding of bacteria and fungi from hard-to-heal wounds to the DACC-coated dressings.
Read Full Scientific Objectives & Methods
This is a prospective, open, single-centre, exploratory clinical investigation with a primary objective of studying the binding of bacteria and fungi from hard-to-heal wounds to the surface of DACC-coated dressings. Subjects suffering from hard-to-heal wounds who are due to start using a dressing from the Sorbact range will be recruited at one investigation site in Sweden. The subjects will be divided into three groups by dressing type and there will be 10 subjects in each group, i.e., 10 subjects will be treated with Sorbact® Compress, 10 subjects will be treated with Sorbact® Gel Dressing, and 10 subjects will be treated with Sorbact® Ribbon Gauze. The dressings will be used in accordance with their respective IFU. The clinical investigation is designed to have a treatment period of 14 days with no additional follow-up. Three visits are planned for each subject, including a screening/baseline visit at the clinic and two further visits to the study clinic.
Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Compress has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds. The purpose of the study is not to compare between the devices, but to study each device on its own.
Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Gel Dressing has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds. The purpose of the study is not to compare between the devices, but to study each device on its own.
Sorbact® technology is a bacteria- and fungi-binding wound contact layer from which Sorbact® Ribbon Gauze has been developed. The patients will be in one of these 3 arms depending on the choice of dressing most suitable for their wounds. The purpose of the study is not to compare between the devices, but to study each device on its own.
Treatment Arms Description
Patients already assigned to start treatment with Sorbact® Compress as it is judged by the investigator to be the most suitable for their wounds
Patients already assigned to start treatment with Sorbact® Gel Dressing as it is judged by the investigator to be the most suitable for their wounds
Patients already assigned to start treatment with Sorbact® Ribbon Gauze as it is judged by the investigator to be the most suitable for their wounds
- Able to read and understand the Subject Information and Informed Consent Form and provide meaningful informed consent
- Due to start using one of the following dressings: Sorbact® Compress, Sorbact® Gel Dressing and Sorbact® Ribbon Gauze
- Age ≥18 years
- Presence of hard-to-heal wound for ≥6 weeks with no significant wound area reduction for the last 4 weeks confirmed by investigator/study nurse
- Participating in another clinical investigation
- Known allergy or sensitivity to any components of the allocated investigational device
- Use of antimicrobial agent (e.g., silver- or iodine-containing dressings, or gels) during the last wo weeks
- Use of a dressing from the Sorbact® range during the last two weeks
- Subjects with any other condition that as judged by the investigator may make investigation procedures inappropriate
Primary Outcome Measures
- Bacterial and fungal species irreversibly bound to the dressing after 2 days (+ 1 day). — Time Frame: 2 days (+1 day)
The measurements that will be used to assess the primary outcome are 16S rRNA sequencing to identify bacterial species, Internal Transcribed Spacer (ITS) sequencing to identify fungal species and scanning electron microscopy (SEM) images for visualization of bacteria and fungi bound to the dressing
View Secondary Outcome Measures (3)
- Wound bed microbial load at 14 days (±1 days) compared to baseline — Time Frame: 14 days (±1 days)
qPCR (quantitiative polymerase chain reaction) will be used.
- Wound bed bacteria and fungi species at baseline and at 14 days (±1 days) — Time Frame: 14 days (±1 days)
16S rRNA and Internal Transcribed Spacer (ITS) sequencing will be used.
- Wound fluid inflammatory biomarker levels at 14 days (±1 days) compared to baseline — Time Frame: 14 days (±1 days)
PEA (proximity extension assay) will be used.
This trial is recruiting at 1 study facilities worldwide. Click below to see if there is a clinic or hospital in your area:
Show All 1 Facilities & Contact Sites
Want to apply or inquire about joining this study? Fill out this simple questionnaire, and our assistant will instantly generate a professional email draft you can copy and send to the central contact coordinator listed above!
View Official Medical/Scientific Title
An Open, Single-centre, Clinical Investigation to Explore the Binding of Bacteria and Fungi to Dialkylcarbamoyl Chloride (DACC)-Coated Dressings From Hard-to-heal Wounds